Table 2.

Clinical outcomes

Dose level	Median number of cycles (range)	Immune response	Individual patient PFS in months	Individual patient OS in months
500 ug (n=5)	4 (2–6)	unknown	1.4, 4.8, 4.9	7.8, 19.3, 20.6
		no	4.5	14.9
		yes	8.3	48.9
750 ug (n=5)	4 (1–9)	no	1.1, 1.9, 3.7,15.8	3.4, 4.0, 7.2, 51.2+
		yes	4.6	24.7
1000 ug (n=5)	1 (1–2)	unknown	0.9	2.1
		no	1.0, 1.0, 1.1, 1.8	6.3, 7.5, 9.9, 18.9
1250 ug (n=5)	1 (1–3)	unknown	0.9, 0.9, 1.0	1.4, 3.1, 5.3
		no	2.7, 2.8	7.6, 17.4
1500 ug (n=3)	4 (3–7)	no	2.8	7.2
		yes	4.2, 10.3	6.2, 24.0
1750 ug (n=5)	2 (1–6)	unknown	1.0	18.6
		no	1.1, 1.9, 2.1, 8.2	2.7, 3.2, 10.4, 27.2+
2000 ug (n=6)	4 (1–12+)	unknown	0.7	7.2
		no	1.1, 4.8, 5.6, 8.3,	7.5, 14.1+,16.8+, 17.9+
		yes	19.5+	22.2+

^*bold faced numbers indicate patients who had a 2–4 fold increase in at least one tetramer positive CTL